{"nctId":"NCT01407575","briefTitle":"Buprenorphine for Treatment Resistant Depression","startDateStruct":{"date":"2011-09"},"conditions":["Depression","Depressive Disorder","Depressive Disorder, Major"],"count":13,"armGroups":[{"label":"Buprenorphine","type":"EXPERIMENTAL","interventionNames":["Drug: Buprenorphine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Buprenorphine","otherNames":["suboxone","buprenex","temgesic","subutex"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 21 and older\n* Major depressive disorder\n* Non-responder to at least 2 FDA-approved antidepressants prescribed at a therapeutic dose, each for at least 6 weeks, or is a depression non-responder from an ongoing study of late-life depression at our research clinic.\n* For women of child-bearing age, must have negative pregnancy test and agree not to get pregnant while participating.\n\nExclusion Criteria:\n\n* Concomitant use of strong or moderate CYP3A4 inhibitor.\n* Refusal to stop all opioids.\n* Refusal to discontinue all alcohol.\n* Refusal to discontinue benzodiazepines other than the equivalent of lorazepam 2 mg/day prescribed at a stable dose for at least the past 2 weeks.\n* Hepatic impairment (AST/ALT \\> 1.5 times upper normal).\n* Lung disease requiring supplemental oxygen (CPAP for sleep apnea is acceptable).\n* Estimated creatinine clearance \\<30 mL/min.\n* Inability to provide informed consent.\n* Depressive symptoms not severe enough (i.e., MADRS \\< 10) at the baseline assessment.\n* Dementia, as defined by MMSE \\< 24 and clinical evidence of dementia\n* Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms.\n* Abuse of or dependence on alcohol or other substances within the past 3 months.\n* Meets criteria for history of abuse or dependence upon opioids.\n* High risk for suicide.\n* Contraindication to buprenorphine.\n* Inability to communicate in English.\n* Non-correctable clinically significant sensory impairment.\n* Unstable medical illness.\n* Subjects taking psychotropic medications that cannot be safely tapered and discontinued prior to study initiation.","healthyVolunteers":false,"sex":"ALL","minimumAge":"21 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Montgomery Asberg Depression Rating Scale","description":"measure of depression severity Theoretical Range 0-60 lower values represent better outcome","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.8","spread":"10.96"},{"groupId":"OG001","value":"32.6","spread":"2.07"}]}]}]},{"type":"PRIMARY","title":"Blood Pressure","description":"Measure of systolic and diastolic blood pressure. 140/90 or lower is considered normal and indicates a better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"138.4","spread":"22.71"},{"groupId":"OG001","value":"117.2","spread":"28.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":"14.92"},{"groupId":"OG001","value":"71","spread":"15.92"}]}]}]},{"type":"PRIMARY","title":"UKU Side Effect Rating Scale","description":"measure of side effects 46 items with scores of 0,1,2,3 possible. Theoretical range 0-138 Lower scores indicate fewer side effects","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.2","spread":"13.74"},{"groupId":"OG001","value":"20.2","spread":"5.36"}]}]}]},{"type":"SECONDARY","title":"Brief Symptom Inventory -- Anxiety Subscale","description":"measure of anxiety Lower numbers indicate better outcome Theoretical Range 0-2.4","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.43","spread":"1.1"},{"groupId":"OG001","value":"0.97","spread":"0.74"}]}]}]},{"type":"SECONDARY","title":"Positive and Negative Affect Scale","description":"Positive Affect Score: Scores can range from 10 - 50, with higher scores representing higher levels of positive affect.\n\nNegative Affect Score: Scores can range from 10 - 50, with lower scores representing lower levels of negative affect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.75","spread":"0.96"},{"groupId":"OG001","value":"16.25","spread":"2.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":"11.4"},{"groupId":"OG001","value":"20.5","spread":"1.73"}]}]}]},{"type":"PRIMARY","title":"Heart Rate","description":"Heart Rate (Beats per minute) 60-100 beats per minute is considered normal lower heart rate represent healthier outcome","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.25","spread":"12.84"},{"groupId":"OG001","value":"72.6","spread":"19.73"}]}]}]},{"type":"PRIMARY","title":"Weight","description":"Participant weight","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"191.7","spread":"30.02"},{"groupId":"OG001","value":"203.7","spread":"12.99"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":7},"commonTop":[]}}}